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storage of the pictures and their comparison over time. Few studies have
compared optical dermoscopy and SDDI from an economic perspective.
Document type : Article de périodique (Journal article)
Référence bibliographique
Tromme, Isabelle ; Devleesschauwer, Brecht ; Beutels, Philippe ; Richez, Pauline ; Praet, Nicolas ;
et. al. Selective use of sequential digital dermoscopy imaging allows a cost reduction in the
melanoma detection process: a belgian study of patients with a single or a small number of atypical
nevi.. In: PLoS One, Vol. 9, no. 10, p. e109339 (2014)
DOI : 10.1371/journal.pone.0109339
Selective Use of Sequential Digital Dermoscopy Imaging
Allows a Cost Reduction in the Melanoma Detection
Process: A Belgian Study of Patients with a Single or a
Small Number of Atypical Nevi
Isabelle Tromme1*, Brecht Devleesschauwer2, Philippe Beutels3, Pauline Richez1, Nicolas Praet4,
Laurine Sacre´1, Liliane Marot1, Pascal Van Eeckhout1, Ivan Theate1, Jean-Franc¸ois Baurain5,
Julien Lambert6, Catherine Legrand7, Luc Thomas8, Niko Speybroeck2
1Department of Dermatology, Centre du Cancer, Cliniques Universitaires St Luc, Universite´ catholique de Louvain, Brussels, Belgium, 2 Institute of Health and Society,
Faculty of Public Health, Universite´ catholique de Louvain, Brussels, Belgium, 3Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious
Disease Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium, 4Department of Biomedical Sciences, Institute of Tropical Medicine,
Antwerp, Belgium, 5Department of Medical Oncology, Centre du Cancer, Cliniques Universitaires St Luc, Universite´ catholique de Louvain, Brussels, Belgium,
6Department of Dermatology, Universitair Ziekenhuis, Antwerp, Belgium, 7 Institute of Statistics, Biostatistics and Actuarial Sciences, Universite´ catholique de Louvain,
Louvain-la-Neuve, Belgium, 8Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud, Pierre Be´nite, France
Abstract
Background: Dermoscopy is a technique which improves melanoma detection. Optical dermoscopy uses a handheld
optical device to observe the skin lesions without recording the images. Sequential digital dermoscopy imaging (SDDI)
allows storage of the pictures and their comparison over time. Few studies have compared optical dermoscopy and SDDI
from an economic perspective.
Objective: The present observational study focused on patients with one-to-three atypical melanocytic lesions, i.e. lesions
considered as suspicious by optical dermoscopy. It aimed to calculate the ‘‘extra-costs’’ related to the process of melanoma
detection. These extra-costs were defined as the costs of excision and pathology of benign lesions and/or the costs of
follow-up by SDDI. The objective was to compare these extra-costs when using optical dermoscopy exclusively versus
optical dermoscopy with selective use of SDDI.
Methods: In a first group of patients, dermatologists were adequately trained in optical dermoscopy but worked without
access to SDDI. They excised all suspicious lesions to rule out melanoma. In a second group, the dermatologists were
trained in optical and digital dermoscopy. They had the opportunity of choosing between immediate excision or follow-up
by SDDI (with delayed excision if significant change was observed). The comparison of extra-costs in both groups was made
possible by a decision tree model and by the division of the extra-costs by the number of melanomas diagnosed in each
group. Belgian official tariffs and charges were used.
Results: The extra-costs in the first and in the second group were respectively J1,613 and J1,052 per melanoma excised.
The difference was statistically significant.
Conclusions: Using the Belgian official tariffs and charges, we demonstrated that the selective use of SDDI for patients with
one-to-three atypical melanocytic lesions resulted in a significant cost reduction.
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Introduction
Cutaneous melanoma is one of the prime causes of death by
cancer in the young Caucasian adult population [1]. Incidence,
expressed as lifetime risk, is around 1–2% in Western Europe and
the US and is still increasing in many countries [2]. Early detection
and immediate surgery is the most effective treatment in reducing
mortality. In order to favor this early detection, a technique called
‘‘dermoscopy’’ has been introduced in 1980s.
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Optical dermoscopy (OD) is a non-invasive technique that uses
a handheld, magnifying, optical device that suppresses light
reflection by the stratum corneum either by liquid immersion or
by cross-light polarization. It allows the observation of features
invisible to the naked eye. Its efficacy to improve diagnostic
accuracy for melanoma in a clinical setting has been proven in a
meta-analysis [3]. However, this improvement is linked to
examiners’ training and experience in the technique [4].
Sequential digital dermoscopy imaging (SDDI) allows the
storage and retrieval of dermoscopic images, offering a time-lapse
comparative analysis of the cutaneous pigmented lesions at
different time intervals. The main interest of the technique relates
to atypical melanocytic lesions, which are impossible to diagnose
by OD as being either benign nevi or very early melanomas.
Besides pathological examination, which requires prior excision
and diagnoses the nature of the lesions, only the monitoring of the
evolution of the lesions helps determining its benign or malignant
nature. SDDI has been proven to favor earlier melanoma
detection, including melanomas lacking clinical and dermoscopic
features for melanoma (so-called ‘‘featureless melanomas’’) [5–8].
The literature about SDDI often focuses on its use in patients with
a large number of nevi. Nevertheless, SDDI is also commonly used
to monitor a single or a small number of atypical melanocytic
lesions [9,10].
Both OD and SDDI have two main objectives: (i) to enhance
sensitivity in the melanoma detection, (ii) to increase specificity
through reduction of unnecessary excisions of benign lesions.
The present observational study, performed in a clinical setting,
focused on patients with one-to-three atypical melanocytic lesions
(i.e., lesions considered as suspicious by OD examination) and
studied them from a medico-economic point of view. The
objective was to compare the costs related to the process of
melanoma detection in two situations: (i) the dermatologist, well
trained in OD but without access to SDDI, was obliged to excise
the lesions to exclude a melanoma, (ii) the dermatologist, well
trained in OD and SDDI, had the choice between excision upfront
or follow-up by SDDI, leading or not to subsequent excision.
Materials and Methods
Design overview
The present study is a cost comparison of two intervention
options for patients presenting to dermatologists because of the
patient’s concern for melanoma, and having one-to-three atypi-
cal/suspicious nevi. The two options were: (i) excision of all
suspicious lesions and (ii) excision of highly suspicious and SDDI of
slightly or moderately suspicious lesions. It is an observational
study of the two options in terms of costs with a common clinical
outcome (excisions of benign lesions per patient). We use the
observations in a decision tree model to make inferences on the
incremental costs between the two patient groups (on a per-patient
basis through bootstrapping).
We used the database of the DEPIMELA observational study
presented elsewhere [11]. In brief, the inclusion period of the
DEPIMELA study ran from 1/10/2009 to 30/9/2010. The
present study included all the consecutive patients with one-to-
three atypical melanocytic lesions seen during the DEPIMELA
study by (i) dermatologists who used OD with adequate training
(Group 1) and (ii) dermatologists who used OD and who, in
addition, had access to SDDI, with adequate training in both
techniques (Group 2). Patients with more than three atypical nevi
were excluded from this study. Patients who were already
monitored by SDDI for atypical nevi were also excluded. The
lesions monitored by SDDI were selected atypical melanocytic
lesions. The dermatologists having access to SDDI used the latter
only if they considered it helpful in addition to OD (i.e., for
difficult lesions). This is referred to as ‘‘selective use of SDDI’’.
The main aim of this study was to compare the costs related to
the process of melanoma in Groups 1 and 2. We excluded the
costs of melanoma excisions and pathology because these should
be the same for each correctly diagnosed melanoma, irrespective
of which group they belonged to. Because of this exclusion, the
costs were referred as ‘‘extra-costs’’ in this paper. In Group 1, the
extra-costs included costs of excision and pathology of benign
lesions excised. In Group 2, the extra-costs included costs of SDDI
and/or costs of excision and pathology of benign lesions excised.
OD was performed with a Delta 20 Dermoscope (Heine,
Herrshing, Germany) or a Dermoscope DermoGenius Basic II
(Linos Photonics, Munich, Germany). For SDDI, the dermatol-
ogists in our study used the FotoFinder Dermoscope (Teachscreen
Software, Bad Birnbach, Germany).
Reference diagnosis was pathological analysis in Group 1,
pathological analysis or stability of the SDDI picture after a
minimum of three months in Group 2.
The DEPIMELA study was approved on 28 November 2008 by
the ethics committee of the Universite´ catholique de Louvain
(number B40320085012). Part of the medical file was copied by
the dermatologist in a structured document to provide the
elements needed by the study. At that time, the patient gave his
verbal consent, which was acknowledged by the dermatologist. A
written consent was not required in this kind of observational
study. Indeed, the subject of the present survey was the practice of
the dermatologists and the economical consequences of the
technique they used, rather than the patients themselves. The
latter freely chose their dermatologist irrespective of the study (and
were not randomized). The ethics committee approved this
procedure.
Setting and participants
Group 1. Twelve volunteer dermatologists adequately trained
in OD were recruited from French-speaking Belgian private and
hospital practices without access to SDDI. Populations seen by
these dermatologists were not statistically different in terms of age,
sex and risk factors for melanoma (p values.0.1). We included the
following risk factors: (i) a personal history of melanoma, (ii) a
family history of melanoma (at least 2 melanomas in first-degree
relatives), (iii) Fitzpatrick’s skin phototype I (very fair skin) or (iv) a
stay of at least one year in a tropical country before the age of 15.
They were a priori not different in terms of social status and access
to a dermatologist (approximation assessed according to the fact
that all the dermatologists had mixed private/non private
facilities). The dermatologists were considered as adequately
trained if (i) they had received more than ten hours of initial
training in OD and (ii) they maintained self-training. They
included all consecutive patients who had one-to-three melano-
cytic lesions which were excised because of low to high suspicion of
melanoma. Patients who had asked for the excision for cosmetic or
comfort reasons were excluded, if the dermatologist had no doubt
about the benignancy of the lesion.
Group 2. Ten dermatologists from an academic dermatology
department (Cliniques Universitaires St Luc, Brussels, Belgium),
agreed to refer to the department’s pigmented lesion clinic (PLC)
all their patients with any melanoma suspicion and any lesion they
would have removed to exclude a melanoma. The PLC was run
by two dermatologists adequately trained in OD and SDDI. The
PLC dermatologist decided either to excise the lesions or to
monitor these by SDDI. The reasons for excision were: (i) high
suspicion of melanoma in a flat lesion, (ii) any suspicion of
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melanoma in a raised lesion (in order not to miss an advanced
melanoma), and (iii) any suspicion of melanoma if the patient
refused the follow-up by SDDI.
The monitoring by SDDI was conducted after three months
and after nine additional months. Three months is the commonly
accepted interval before the first follow-up [12] and has been
shown to detect 93% of in situ melanomas of the non-lentigo
maligna type and 96% of invasive melanomas [5]. Patients missing
the first check-up were called and offered another appointment. A
second follow-up after one year is ideal to detect the remaining
proportion of so-called ‘‘slow-growing’’ melanomas [13]. This
second follow-up was presented as optional for patients with
moderately atypical lesions and without any of the aforementioned
risk factors for melanoma. In these cases, patients were instructed
to observe their lesion and return if any change was observed.
Excision was performed if any significant change was observed,
according to the literature [7,12].
Outcomes
The present study analysed a part of the DEPIMELA study
database from an economic point of view. The aim was to
compare the extra-costs in both Groups. In Group 1, the extra-
costs included the excision costs of all the benign nevi excised
because of having been considered as suspicious by dermatologists
well trained in OD: in Group 2, the extra-costs included the SDDI
follow-up costs and/or benign lesions excision costs when patients
were monitored in a place where SDDI was available. We first
computed the observed costs in both groups, then the simulated
costs of both groups obtained from a decision-tree model. The
latter allowed us to obtain an idea of the uncertainty of our results.
Costs
Unit costs were based on official tariffs and charges in Belgium
in 2012 [14] (Table 1). Although the coverage of OD and SDDI
by the national Belgian health care system only became effective
on 1/3/2014, we used the 2012 figures because we already knew
their official reimbursement amounts in November 2012. The
SDDI examination official cost includes: (a) total body examina-
tion by OD, (b) electronic storage of atypical nevi dermoscopic
pictures and (c) localization of these nevi on the body. This cost is
added to the cost of the consultation. Currently, the following
restrictions for reimbursement of the SDDI examination costs
apply in Belgium: (i) SDDI is only reimbursed for patients with a
personal history of melanoma, a family history of melanoma (at
least two melanomas in first-degree relatives) or patients with
Atypical Mole Syndrome (AMS) (simplified from Newton Bishop’s
definition:$100 nevi and$2 atypical nevi) [15]; (ii) irrespective of
the number of OD and/or SDDI examinations per year, only one
OD and only one SDDI examinations are reimbursed per year.
Nevertheless, in our comparative cost analysis, we applied these
unit costs to every unit of associated resource use, as if (i) the
reimbursement would be effective for all the patients (irrespective
of their history or phenotype) and (ii) the number of SDDI
reimbursements in a year would not be limited.
The costs were calculated using the currently prevailing
treatment pathways in Belgium. We considered the most common
situation which is the following. The patient is examined during a
first consultation and the possible decision to excise a lesion is
discussed at this time. The excision is performed a few days or
weeks thereafter. The stitches are removed and the scar is checked
by the general practitioner. If several excisions are performed the
same day, the second and the third excision costs are divided by
two and the pathology cost remains the same for one or more
lesions. We took into account the observed number of patients
with two or three excisions made the same day to calculate the
extra-costs. Regarding immunohistochemistry, it is generally
admitted that this is useful to exclude melanomas in cases of nevi
with severe atypia. These nevi are much more frequent in the
second group as demonstrated in the DEPIMELA study [11]. We
assumed that two immunostains (HMB 45 and a cocktail of
antibodies including gp100, tyrosinase and MelanA) were
performed in a number of benign nevi equivalent to the number
of melanomas in each group. In accordance with Belgian
guidelines [16], personal non-medical costs such as travel fare as
well as indirect costs due to absence from work for the
consultations or because of scarring were not taken into account.
Classification bias
It cannot be excluded that some lesions followed by SDDI were
in fact (very) slow-growing melanomas. Nevertheless, the vast
majority of the patients continued to be monitored in our
institution. We have, therefore, followed up these patients for
more than three years. In addition, it cannot be excluded that
some melanomas could have been missed in the first group but
would have been correctly diagnosed if included in the second
group.
Selection bias
Social status and access to a dermatologist were not measured
and can therefore be considered as a potential bias.
Data analysis
Both groups were compared using a cost comparison focused on
the costs of unnecessary excision and/or follow-up costs. These
costs were defined as ‘‘extra-costs’’ because the costs of melanoma
excisions and pathology were not taken into account (these should
be the same for each correctly diagnosed melanoma, irrespective
of which group they belonged to). The extra-costs were calculated
by patient and not by lesion because several lesions were excised or
monitored by SDDI at the same time, which reduced the costs per
patient in both cases. The extra-costs were then divided by the
number of melanomas detected in each group, to obtain an
‘‘additional cost per diagnosed melanoma’’.
Statistical analysis
A decision-tree model was developed to assess the statistical
significance of the total extra-cost difference between both groups
[17]. A probabilistic sensitivity analysis (PSA) was integrated in the
model to express parameter uncertainty [18]. Data derived
parameter distributions were defined based on the clinical
characteristics of both groups (Table 2), and the unit costs listed
in table 1 were attributed on the simulated values drawn from
these parameter distributions. All calculations were performed in
R 3.0.1 (R Core Team, 2013) [19]. For each of the 10,000
iterations of the model, a value was sampled from each parameter
distribution, such that a distribution of 10,000 estimates was
obtained from each outcome (with the cost difference between
both groups being the primary outcome of interest). We will report
the proportion of iterations resulting in OD being more expensive
than selective SDDI. To assess which input parameters had the
greatest influence on the variability in the overall output, i.e. the
cost difference between both groups, we complemented the PSA
with a variable importance analysis. We calculated standardized
regression coefficients as a measure of variable importance. These
were obtained by first standardizing the input parameters and the
output (i.e. subtracting the mean and dividing by the standard
deviation), and subsequently regressing the standardized input
Sequential Digital Dermoscopy Imaging Lowers Melanoma Detection Costs
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e109339
parameters against the standardized output. R code is available as
supplementary file to the manuscript (Code S1).
Results
Patients’ progress in Group 1 and 2 are summarized in
Figure 1.
Group 1
Of the 7,434 patients examined during one year for melanoma
detection, 603 were eligible for this study and underwent surgery.
There was no patient with more than three atypical/suspicious
nevi who had to be excluded (probably because patients with
many atypical nevi were either referred to a PLC or underwent
regular excisions of their new atypical/suspicious nevi). The mean
age of these 603 patients was 41 years (from 4 to 86 years) and the
sex ratio (M:F) was 0.57. Six hundred and forty excisions were
performed, leading to the diagnosis of 70 melanomas. The
melanoma/non-melanoma ratio (M/NM-R) was 1/8.14. Regard-
ing benign lesions, excision and pathology observed costs were
J112,920, which can also be expressed as J1,613 for every
melanoma excised.
Group 2
During the same year, 1,926 patients were examined for
melanoma detection and 219 were eligible for the present study.
The mean age of these 219 patients was 39 years (from 14 to 88
years) and the sex ratio (M:F) was 0.58. Eighty-eight patients
required immediate excision of suspicious lesions, leading to the
diagnosis of 29 melanomas. Seven patients underwent excision
because they refused the SDDI monitoring; all these lesions were
diagnosed as benign by pathology. The 124 remaining patients
agreed to be monitored by SDDI for a total of 157 lesions. The
short-term follow-up was planned after three months. Six patients
missed their appointment and were re-contacted. Finally, all the
124 patients were examined within six months. Eleven lesions had
changed after 3 months and were excised, three of these were
melanomas. A second check by SDDI after one year was suggested
to the 113 remaining patients. The dermatologists insisted on the
importance of this examination in patients with very atypical
lesions and/or with identified other melanoma risk factors. All
these patients came to this one year appointment, as well as many
other patients of this group, even if this appointment had been
presented to them as optional. Only 23 patients did not show-up
after 18 months. They all were clearly informed they had to
observe their nevi and to request a visit in case of change.
However, none came back for this reason. The second follow-up
visit led to the excision of five monitored lesions, which were all
diagnosed as benign by pathology. Finally, 32 melanomas and 79
non-melanomas were excised: the total M/NM-R was 1/2.47.
The three melanomas excised after the short-term SDDI visit were
in situ for two of them and very early invasive (Clark level II,
Table 1. Current unit costs in Belgium (2012), expressed in Euros.
Item Cost
Dermatologist’s consultation cost 28.88
General practitioner’s consultation cost 23.67
Cutaneous tumor excision with suture 54.10
Second cutaneous tumor excision with suture 27.05
Cutaneous tumor(s) pathology 62.02
Immunohistochemistry 25.41
Optical dermoscopy 6.39
Sequential digital dermoscopy imaging 23.22
Costs are the same in academic hospitals and non-academic hospitals or private practices.
doi:10.1371/journal.pone.0109339.t001
Table 2. Parameter distributions for probabilistic uncertainty analysis.
Parameter
Group 1
Distribution
Group 1
Mean
Group 1
Range
Group 2
Distribution
Group 2
Mean
Group 2
Range
Number of patients with unnecessary excisions Binomial
(7434, 533/7434)
533 490–577 Binomial
(1926, 79/1926)
79 62–96
Proportion of patients with
.1 unnecessary excision
Beta (33, 500) 0.06 0.04–0.08 0 – –
Average number of unnecessary excisions per patient Gamma (570, 533) 1.07 0.98–1.16 1 – –
Number of excised Melanomas Poisson (70) 70 54–87 Poisson (32) 32 21–44
Number of patients registered by SDDI at inclusion time – – – Poisson (124) 124 103–146
Proportion of patients followed up by SDDI at 3–6 months – – – 1 – –
Proportion of patients followed up by SDDI at 12 months – – – Beta (90, 34) 0.73 0.64–0.80
SDDI = Sequential Digital Dermoscopy Imaging.
The mean is defined as the mean of the distribution. The range is constructed as the 2.5th and 97.5th of the concerned distribution. We assumed the different
parameters in that table to be independent.
doi:10.1371/journal.pone.0109339.t002
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0.2 mm of Breslow’s thickness) for the remaining case. The total
observed extra-cost was J33,658 and was nearly equally
distributed between excision and pathology costs (J17,233) and
SDDI follow-up costs (J16,425). The extra-cost, for each
melanoma excised, was J1,052 in Group 2. The follow-up period
for the DEPIMELA study was one year. In addition, most patients
have been seen in the institution during the following 2.5 years and
any melanoma was reported.
Comparison of Group 1 and Group 2
The observed total direct extra-costs in Group 1 versus Group 2
are shown Figure 2. This figure shows also the decision-tree model
which was used to simulate the extra-costs resulting from
melanoma detection. Parameter distributions for probabilistic
uncertainty analysis are presented in Table 2. Through this
probabilistic uncertainty analysis we estimated the mean cost
difference between Group 2 and Group 1 at J548 (95% credibility
interval: 65–1856) (Figure 3, Table 3). The extra-costs per
melanoma excised presented in Table 3 (J1,633 in Group 1
and J1,085 in Group 2) and the extra-cost per melanoma excised
presented in Figure 2 (J1,613 in Group 1 and J1,052 in Group 2)
are different because the first ones were simulated and the second
ones were observed. The proportion of iterations, resulting in OD
being more expensive than selective SDDI, was equal to 96.5%. At
a 5% significance level, this indicates a significant statistical
difference between the extra-costs in both groups. Figure 4 shows
the tornado graph (i.e., standardized regression coefficients of the
different parameters, ranked according to their absolute values).
The coefficients reflect how many standard deviations the output
will change per standard deviation increase in an input. The
largest source of uncertainty is, logically, the number of excised
melanomas in both groups (denoted ‘‘Mela OD’’ and ‘‘Mela
SDDI’’). The R-squared of the variable importance regression
model was 0.95.
Discussion
The present observational study, performed in a clinical setting,
focused on patients with one-to-three suspicious melanocytic
lesions (i.e., lesions considered as suspicious by OD examination)
and studied them from a medico-economic point of view. From a
sample of 822 patients, we showed that, when a dermatologist well
trained in dermoscopy had the choice between excision and
follow-up by SDDI (leading or not to subsequent excision), the
extra-costs were statistically lower than if he was obliged to excise
the lesions in order to rule out melanoma. Extra-costs included
costs of SDDI and/or costs of excision and pathology of benign
lesions excised.
To the best of our knowledge, this is the first medico-economic
study on SDDI. This technique is reimbursed in Belgium and in
several other European countries but, in most countries, only for
patients at high risk for melanoma (i.e., mainly patients with
personal history of melanoma and/or AMS). It has probably been
assumed that SDDI is cost-effective in these groups. We studied
patients with one-to-three suspicious melanocytic lesions. Most of
them were at low risk for melanoma. In the Belgian context, the
costs borne by these patients are higher with selective SDDI
follow-up (where reimbursement is not covered) than in the case of
Figure 1. Study flowchart. The evolution of the patients is divided into two groups. In Group 1, patients were examined by dermatologists
adequately trained in optical dermoscopy (OD). In Group 2, patients were examined by dermatologists adequately trained in optical dermoscopy and
who had access to sequential digital dermoscopy imaging (SDDI).
doi:10.1371/journal.pone.0109339.g001
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systematic excision (which is completely reimbursed). However, we
have shown that the costs borne by the national health care system
were higher in the case of systematic excision, including if the
SDDI costs are reimbursed without restriction. As a result, we
believe that, in Belgium, all patients’ SDDI costs should be
reimbursed.
We excluded patients with many atypical nevi because most of
them are classified in the AMS [15]. This syndrome increases the
melanoma risk, not only because a melanoma can arise on an
atypical nevus but, predominantly, because the skin of these
patients is at high risk of generating melanomas from isolated
melanocytes. Therefore, these patients must, ideally, be monitored
by SDDI for many years and the method of analyzing the costs of
this follow-up should be different from the method used in the
present study.
Figure 2. Observed total direct extra-costs distributed in the decision-tree model. This figure shows the observed total direct extra-costs
distributed in a decision tree model. In Group 1, patients were examined by dermatologists adequately trained in optical dermoscopy (OD). In Group
2, patients were examined by dermatologists adequately trained in optical dermoscopy and who had access to sequential digital dermoscopy
imaging (SDDI). *Melanoma excision costs are not taken into account because these should be the same for each correctly diagnosed melanoma,
irrespective of which group they belonged to.
doi:10.1371/journal.pone.0109339.g002
Figure 3. Histogram of the estimated extra costs of sequential digital dermoscopy imaging versus optical dermoscopy. The extra-
costs are defined as the costs of excision and pathology of benign lesions and/or the costs of follow-up by sequential digital dermoscopy imaging.
These extra-costs are divided by the number of melanomas diagnosed in each group.
doi:10.1371/journal.pone.0109339.g003
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The present study focused on patients with one-to-three
suspicious melanocytic lesions, divided into two groups. In Group
1, patients were examined by dermatologists adequately trained in
OD. In Group 2, patients were examined by dermatologists
adequately trained in OD and having access to SDDI if needed.
The extra-costs in the first and in the second group were
respectively J1,613 and J1,052 per melanoma diagnosed. The
gain linked to SDDI selective use was more than J500 per
melanoma diagnosed. Since the acquisition cost of the SDDI
equipment was around J20,000 in 2012, its appropriate use in
hospitals could win back the excess investment for the health care
payer to correctly diagnose melanoma (even when ignoring
SDDI’s benefits to AMS patients, as we did here). Nevertheless,
irrefutable evidence of this would require specific prospective
studies.
The cost difference between both groups is closely related to the
M/NM-Rs differences. The M/NM-Rs were 1/8.14 in Group 1
and 1/2.47 in Group 2. It could be argued that this difference
between both M/NM-Rs was linked to a higher level of
experience in OD in Group 2. However, the skill level in OD is
limited by the technology itself. Most atypical nevi cannot be
differentiated from very early melanomas and their evolution over
time is the only way to have more information. It could also be
argued that this difference was partially due to a different
population in a University hospital (Group 2). Interestingly, if all
the lesions considered as moderately suspicious and monitored by
SDDI without final excision had been added to the non-melanoma
lesions excised in Group 2, the M/NM-R in Group 2 would be 1/
7.78. This number is not statistically different from the 1/8.14 in
Group 1 (p value = 0.2).
Even with the availability of SDDI, the number of excised
benign lesions will never be reduced to zero for several reasons: (i)
raised ambiguous melanocytic lesions should not be monitored
because of the risk of missing an advanced melanoma, (ii) excision
of Spitz nevi is generally recommended, even if it is controversial
for typical lesions in children [20], (iii) some clinically and
dermoscopically atypical nevi mimic melanomas and will always
be excised.
Kittler et al. found in an experimental study that the possibility
of follow-up by SDDI reduced the number of benign excised
lesions, but only by very experienced dermoscopists [21]. This
allows us to insist on the fact that our results cannot be
extrapolated to beginners in dermoscopy: if the excision rate does
not decrease thanks to SDDI availability, the costs would probably
be higher in the second group. As mentioned by Kittler et al in the
same publication [21], compliance is a critical point for the success
Table 3. Simulated costs of excision, pathology and/or follow-up of benign lesions, expressed in Euros (mean+95% credibility
interval).
Group 1a Group 2a Differenceb
Excisions* 76,536 (70,314–82,850) 10,710 (8403–13,011) 65,82 (60,289–78,320)
Pathology** 36,394 (33,512–39,355) 6529 (5240–7893) 29,86 (27,160–35,586)
Follow-up by SDDI*** - 16,419 (13,510–19,475) 216,419 (218,967– 210,971)
Total 112,929 (103,947–121,967) 33,658 (29,052–38,257) 79,271 (70,902–98,963)
Total/melanoma diagnosed 1633 (1289–2091) 1085 (758–1588) 548 (65–1856)
*Includes consultations, optical dermoscopy in Group 1, and surgery.
**Includes classical pathology and immunohistochemistry for very atypical nevi.
***Includes consultations and sequential digital dermoscopy imaging.
aTwo-sided 95% credibility interval (constructed as the distribution’s 2.5th and 97.5th percentile).
bOne-sided upper 95% credibility interval (constructed as the distribution’s 5th and 100th percentile).
doi:10.1371/journal.pone.0109339.t003
Figure 4. Sensitivity analysis: tornado graph. Mela OD: number of excised melanomas in the optical dermoscopy (OD) group; Mela SDDI:
number of excised melanomas in the sequential digital dermoscopy imaging (SDDI) group; P unnec ex OD: number of patients with unnecessary
excisions in OD group; P unnec ex SDDI: number of patients with unnecessary excisions in SDDI group; P ctrl T0: number of patients registered by SDDI
at inclusion time; P ctrl 12 M: proportion of patients followed-up by SDDI at 12 months; N unnec ex: average number of unnecessary excisions per
patient; Multi unnec ex: proportion of patients with .1 unnecessary excision.
doi:10.1371/journal.pone.0109339.g004
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of monitoring. Our rate of compliance was very good, compared
to other studies [5,22]. Only 3.6% of patients had to be re-
contacted.
This study is not a cost-effectiveness analysis, because only costs
were compared between both groups. A further comparison based
on cost-effectiveness would require relating cost-differences
between the groups to effect-differences. In economic evaluation,
these effect-differences typically include improvements in health
related quality of life (HRQoL) and survival. HRQoL was
expected to be higher in Group 2, because unnecessary surgeries
and scars were avoided. Concerning the survival, the three
melanomas found by SDDI were in situ or very early invasive
(Clark level II, Breslow’s thickness 0.2 mm). In situ melanoma
never metastasize. The 10–20 year melanoma specific survival
rates for melanomas with Clark II level and Breslow thickness ,
0.25 have been reported to be close to 100% (98.3 to 100%)
[23,24]. The other melanoma patients, diagnosed with OD in
both groups, had a life expectancy not linked to the group they
belonged to, but only linked to the stage of their melanoma.
Our analysis provided clear indications that the average per-
patient costs were lower in Group 2 than in Group 1. Although no
statistical testing has been undertaken in the absence of
prospective survival studies, the current consensus in the literature
is that, on average, survival is expected to be similar in both groups
[23,24]. Furthermore, it seems intuitively highly likely that the
HRQoL per average patient was higher in Group 2 than in Group
1, for the reasons we explained above. Therefore, with lower costs,
similar survival, and higher HRQoL, Group 2 was likely to
dominate Group 1. However, since there is no separate study
showing significant effectiveness and since costs and effects are
likely to be correlated, a formal economic evaluation alongside a
prospective clinical trial would be required to provide irrefutable
evidence on this matter [25]. Perhaps our study can serve as a
further incentive to set up such a (albeit costly) study. Fundamen-
tally our study is limited by the relatively small sample of patients
diagnosed by SDDI plus the lack of any study comparing OD
versus OD and selective use of SDDI in terms of effectiveness in
the general population, let alone in terms of cost-effectiveness.
Regarding SDDI literature, on the one hand, a meta-analysis of
14 SDDI studies concluded on the safety of the technique that
among 383 melanomas detected, more than half were in situ and
the rest were early invasive melanomas (thickness always thinner
than 1 mm) [26]. All these melanomas had an excellent prognosis
but the thickest ones had a low risk of metastasis. It is, however,
unclear whether the slightly later detection of the melanomas
excised because of a change on SDDI pictures would have had an
impact on melanoma-related mortality. On the other hand, more
than half of melanomas detected by SDDI are ‘‘featureless
melanomas’’, i.e. melanomas which would perhaps have been
missed by OD [7]. Finally, the benefit of very early detection
should be weighed against the risk of significant progression of
monitored melanomas, which is probably very low but not equal
to zero. Nevertheless, regarding the SDDI use in a very large
number of PLC in the world, we can conclude that experts in
dermoscopy assume SDDI to be safe (when performed by
experienced dermoscopists in compliant patients).
Our results can only partially be extrapolated to other countries
where SDDI is not reimbursed or where the price and/or the
conditions of reimbursement are very different from those chosen
in this study. The price of consultations, excisions and pathology
vary also from one country to another. Our results should be
confirmed by a multicenter randomized study and could be
extrapolated to other countries if the same calculations are made
using the specific prices of each country.
Our study has some limitations. The excision and pathology of
benign lesions are probably not always useless: some very
dysplastic nevi and some atypical Spitz nevi, despite a final
diagnosis of benignancy, will be treated as melanomas because the
pathologist cannot completely exclude a melanoma diagnosis
[20,27]. Nevertheless, these cases are rare. This is an observational
study and therefore patients were not randomized between the two
groups. The potential bias are the following. First, it cannot be
excluded that some lesions from Group 2, considered as benign
after a three or twelve month follow-up, were slow-growing
melanomas and had been lost from our follow-up. The subgroup
of so-called ‘‘slow-growing melanomas’’ is diagnosed by SDDI
after a median period of 20 months [13]. The prevalence of such
melanomas is unknown but seems to be low. Even if very rare
cases are diagnosed by SDDI after more than five years, the risk of
having missed such melanomas in our study is extremely low.
Return to the PLC if any change was observed could be
burdensome to patients. If only one melanoma was missed, we
must consider two extreme situations. If the melanoma was
diagnosed in a very early stage (in situ or Clark II), our conclusions
are unchanged because the extra-costs per melanoma in Group 2
would be lower. If the melanoma was diagnosed in an advanced
stage, the use of SDDI must then be considered as unsafe. Second,
it is possible that some featureless melanomas were missed in
Group 1 and would have been diagnosed by SDDI. Although
SDDI permits an earlier diagnosis due to the identification of the
so-called ‘‘featureless melanomas’’ [5–8], melanoma prevalence
was probably similar in both groups. In terms of costs, this
difference should not influence the detection costs, but perhaps the
treatment costs. Third, according to some authors, part of the
in situ melanomas would be indolent forms without metastatic
potential [28]. The proportion of in situ/invasive melanomas is
not statistically different in both groups (p value.0,1). Neverthe-
less, as this proportion is high (around 1/1.7), if we had to remove
all the in situ melanomas from our study, our sample sizes would
become smaller and our results may therefore no longer be
statistically significant. Fourth, reimbursement driven unit costs
from home to hospital were not taken into account. This could
perhaps have increased the extra-costs in Group 2. Although
reimbursement driven unit costs are generally low in Belgium, this
might not be the case in countries with a lower population density
and/or a lower dermatologist to patient ratio. Fifth, social status
and access to a dermatologist were not measured and can
therefore be considered as a potential bias.
Conclusion
Assuming that SDDI would be reimbursed and easily available
to all patients with atypical nevi, the present observational study
showed that selective SDDI reduces the extra-costs in the process
of melanoma detection in patients with one-to-three atypical nevi.
It would be interesting to confirm our results, obtained from a
non-randomized observational study, by a multicenter random-
ized study. When practiced by dermoscopy experts, SDDI allows
the follow-up of benign atypical lesions, avoiding their systematic
excision. The extra-costs, mostly linked to the excision of atypical
nevi mimicking early melanomas, will never be reduced to zero,
but could be significantly reduced by SDDI in certain conditions,
as was described above.
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